0.50Open0.50Pre Close0 Volume660 Open Interest1.50Strike Price0.00Turnover0.00%IV-4.93%PremiumJan 17, 2025Expiry Date0.55Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.72Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Immunic Stock Discussion
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Tuesday, 7th January at 6:30 am
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
– Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 –
– Strengthened Management Team and Board of Directors with Key Hir...
Anything Important?
No comment yet